



| Country Demographics <sup>1, 2</sup>                    |            |
|---|------------|
| Total Population (2018) <sup>1</sup>                    | 2,951,776  |
| Urban Population (% of total, 2018) <sup>1</sup>        | 63.1%      |
| Health expenditure per capita (\$US, 2016) <sup>1</sup> | \$358.8    |
| Health expenditure, total (% of GDP, 2016) <sup>1</sup> | 9.9%       |
| Total births (2013) <sup>2</sup>                        | 41,000     |
| Surviving Infants (2013) <sup>2</sup>                   | 40,000     |
| Life expectancy at birth (years, 2017) <sup>1</sup>     | 74.8 years |
| Number of districts (2013) <sup>2</sup>                 | 51         |

| HBsAg Prevalence <sup>3</sup> |      |
|-------------------------------|------|
| Pre-vaccine HBsAG+ (%)        | 2.6% |

| Liver Cancer as Cause of Cancer Death (in Men) <sup>4</sup> |            |
|---|------------|
| Year: 2018  | Ranking: 4 |

| 2018 Country Comparison in European Region (53 Countries) <sup>5</sup> |         |  |   |                                 |
|--|---------|--|---|---------------------------------|
|  | Armenia | Number of countries with reported coverage | Highest reported coverage in EUR                                    | Lowest reported coverage in EUR |
| HepB3 <sup>5</sup>   | 92%     | 46   | 99% (Albania, Monaco, Turkmenistan)                                 | 52% (Ukraine)                   |
| HepB BD <sup>5</sup>   | 97%     | 22   | 99% (Albania, Azerbaijan, Serbia, Tajikistan, Turkey, Turkmenistan) | 36% (Romania)                   |

| Hepatitis B Immunization Coverage <sup>5</sup> |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
|--|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
|  | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
| HepB3 <sup>5</sup>                             | 55%  | 69%  | 91%  | 93%  | 91%  | 91%  | 78%  | 85%  | 89%  | 93%  | 94%  | 95%  | 95%  | 95%  | 93%  | 94%  | 94%  | 94%  | 92%  |
| HepB BD <sup>5</sup>                           | 97%  | 96%  | 95%  | 95%  | 94%  | 93%  | 92%  | 92%  | 91%  | 92%  | 94%  | 95%  | 95%  | 98%  | 98%  | 98%  | 98%  | 97%  | 97%  |
| DTP3 <sup>5</sup>                              | 93%  | 94%  | 94%  | 94%  | 91%  | 90%  | 87%  | 88%  | 89%  | 93%  | 94%  | 95%  | 95%  | 95%  | 93%  | 94%  | 94%  | 94%  | 92%  |
| BCG <sup>5</sup>                               | 97%  | 96%  | 97%  | 92%  | 96%  | 94%  | 91%  | 94%  | 98%  | 99%  | 95%  | 96%  | 96%  | 99%  | 99%  | 99%  | 99%  | 99%  | 99%  |



Abbreviations: NA= not applicable; NR= no report; HepB BD= birth dose within 24 hours; HepB3= at least 3 doses of HepB vaccine; HBsAG= HepB surface antigen. Data Compiled by Asian Liver Center at Stanford University 2019: World DataBank: World Development Indicators database<sup>1</sup>, WHO Immunization Summary: A statistical reference containing data through 2013<sup>2</sup>, WHO Public Health Significance, Targets, Strategies: HBV country profiles<sup>3</sup>, Global Cancer Observatory: Cancer Today-IARC<sup>4</sup>, WHO Vaccine-Preventable Diseases: Monitoring System. 2019 global summary WHO-UNICEF estimates<sup>5</sup>